Pharmasyntez sends first shipment of cancer medicines to Myanmar

ST. PETERSBURG. Dec 22 (Interfax) - The Pharmasyntez Group of Companies has sent its first shipment of cancer medicines to Myanmar, the company's press service said.

The volume of the first shipment totaled 60,000 vials of the drug, which was produced by JSC "Pharmasyntez-Nord" in St. Petersburg.

The drug is part of chemotherapy regimens for the treatment of malignant tumors in various locations, including the digestive organs, adrenal glands, breasts, and neuroendocrine tumors.

"Myanmar is a friendly country to the Russian Federation and the first country in the Association of Southeast Asian Nations (ASEAN) region to which supplies of Pharmasyntez medicines began as part of the expansion of exports by the group. We hope for long-term cooperation with Myanmar and plan to quickly increase shipment volumes, while simultaneously expanding the portfolio of drugs that will be registered in the country in 2024," Nikita Punia, executive director of the group said.

In 2023, Pharmasyntez also started supplying medicines to Syria, Ecuador and the Dominican Republic.

The Pharmasyntez Group is a large Russian manufacturer of anti-tuberculosis, anti-tumor, anti-retroviral drugs and hospital antibiotics. The company's facilities are located in Irkutsk, Bratsk, Ussuriysk, St. Petersburg, and Tyumen.